APAC / MVC's WHO-Partnered Vaccine a First for Taiwan
As a part of the World Health Organisation’s (WHO) COVID-19 Technology Access Pool (C-TAP), the Medicines Patent Pool has signed a worldwide license with Medigen Vaccine Biologics (MVC) for its…
Immunwork, Inc. was founded in 2014. We focus on the research, development, and commercialization of a class of new drugs, which are created based on our proprietary technology platform, for treating multiple types of cancer, a number of severe indications in autoimmune, osteoporosis, infectious, and central nervous system diseases, pathological blood clots, rejection reaction in organ transplantation, and other selected severe clinical conditions.
Currently, many companies and academic groups are racing to establish new methods for preparing antibody drug conjugates (ADCs), bispecific antibodies, multivalent antibodies, and various forms of immuno-oncology products. It is hopeful that those various advancements will bring about major therapeutic breakthroughs in the treatment of various types of cancer. Our technology platform enables the design of a class of new drugs, which we term “T-ETM pharmaceuticals”. These new drug molecules contain both targeting (T) and effector (E) moieties. As evidenced by the product candidates that have already been designed and prepared, our technology can be used to prepare ADCs, bispecific and multi-specific antibodies, and various products in versatile configurations, which have improved product homogeneity, drug payloads, target-binding valency, and consistency in the manufacturing process. The T-E configurations are expected to achieve increased efficacy and safety.
Our existing portfolio of product candidates has expanded much beyond the scopes of applications being pursued in current “magic bullet” concept and bispecific antibody approaches. The T-E molecular platform should be applicable for designing many more other product candidates not illustrated on this website. As personalized and precision medicine is becoming a major trend in pharmaceutical development, the modular design feature of T-E pharmaceuticals is especially suitable for preparing a new generation of therapeutics.
Together, everyone achieves more! We are seeking corporate partners to collaborate the development of our T-E product candidates or to utilize our T-E technology platform to design new drugs for various disease indications.
Contact
If interested, please email us at BD@immunwork.com.
Immunwork, Inc ｜Nangang District, Taipei City, Taiwan 115 ｜ +886-2789-8773
As a part of the World Health Organisation’s (WHO) COVID-19 Technology Access Pool (C-TAP), the Medicines Patent Pool has signed a worldwide license with Medigen Vaccine Biologics (MVC) for its…
In an important milestone for Taiwan’s biotech industry, Diamond Biofund – one of the territory’s most well-established venture capital (VC) funds – became the first such firm to list on…
The latest pharma news from Taiwan, including Gongwin-KY’s lung cancer drug approval in China, Anxo Pharmaceutical/Genovior Biotech alliance, Taiwan’s Industrial Technology Research Institute (ITRI) and Metagone Biotech’s glaucoma and macular…
Writing in the June edition of DIA’s Global Forum magazine, Ellen Sem, Fengyun (Vicky) Han and Annetta C. Beauregard from Janssen Pharmaceutical Companies of Johnson & Johnson, outline the real-world data…
The latest healthcare and pharma news from Taiwan, including the CDMO Bora Pharmaceutical’s acquisition of Eden Biologics assets, the FDA fast track granted to the Taiwanese biomedical group United Biomedical’s…
The latest news from Chinese pharma, including an overhaul of the country’s patent law; a BioNTech-Fosun tie-up on COVID-19 vaccines; and big R&D subsidies for local companies available in Shanghai.…
Charles Chen of Taiwanese firm Medigen Vaccines Biologics Corp (MVC) shares his career journey, the company’s COVID-19 vaccine strategy, and what MVC’s competitive advantages are. At MVC we have…
Andrew Hexter, VP and GM of Gilead Asia 5 (Hong Kong, Singapore, South Korea, Taiwan and Malaysia), shares the highlights of his past three years leading the diverse region, the…
With Asia covering 60 percent of the world’s population but accounting for just around 30 percent of global pharma spending, it goes without saying that healthcare needs in the region…
Johnsee Lee and Eric Yang of Taiwanese precision medicine diagnostics firm Quark Biosciences outline their technology’s unique characteristics, how it differs from sequencing technologies in terms of cost and speed,…
Louis Cheng, CEO of Taiwanese firm Leadgene Biomedical, introduces the company’s expertise in antibody technologies, his ambitious internationalization plans, and comments on the vital role that companies like Leadgene have…
Taiwan Bio Industry Organization Chairman Dr Johnsee Lee outlines the Taiwanese biopharmaceutical industry’s rapid and coordinated response to the COVID-19 crisis and also explains how Quark Biosciences’ diagnostics and precision…
See our Cookie Privacy Policy Here
